News | May 03, 2021
Gujarat Themis Biosyn Q4FY21 net profit lower at Rs. 5.79 Cr
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
Port chairpersons have been asked to personally supervise logistic operations to ensure unhindered movement of such consignments for berthing of such vessel on top priority in the port
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Subscribe To Our Newsletter & Stay Updated
